A Phase 2 Study to Assess BDTX-1535, An Oral EGFR Inhibitor, in Patients with Non-Small Cell Lung Cancer

Tagrisso (osimertinib) - AstraZeneca

BDTX-1535 - Black Diamond Therap

https://cattendee.abstractsonline.com/meeting/20598/presentation/2281

J. Patel1; A. Spira2; J. Stevenson3; H. Chen4; C. Baik5; S. Gordon6; J.T. Henry7; M. Ahluwalia8; M. Barve9; C. Huang10; J. Edenfield11; M. Johnson12; S. Eathiraj13; J. Hajdenberg13; S. Yurasov13; H. Yu14

Jul 24, 2024